Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,707 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, Oikawa S, Ando K, Ishizuka N, Yamazaki T, Yokoyama K, Murata M, Ikeda Y. Teramoto T, et al. Among authors: ando k. Am Heart J. 2010 Mar;159(3):361-369.e4. doi: 10.1016/j.ahj.2009.11.030. Am Heart J. 2010. PMID: 20211296 Clinical Trial.
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Sugawara M, Goto Y, Yamazaki T, Teramoto T, Oikawa S, Shimada K, Uchiyama S, Ando K, Ishizuka N, Murata M, Yokoyama K, Uemura Y, Ikeda Y; Japanese Primary Prevention Project (JPPP) Study Group. Sugawara M, et al. Among authors: ando k. Am J Cardiovasc Drugs. 2019 Jun;19(3):299-311. doi: 10.1007/s40256-018-0313-0. Am J Cardiovasc Drugs. 2019. PMID: 30565155 Clinical Trial.
Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese.
Yokoyama K, Ishizuka N, Uemura N, Mizokami Y, Hiraishi H, Murata M, Uchiyama S, Teramoto T, Shimada K, Yamazaki T, Oikawa S, Sugawara M, Ando K, Ikeda Y; JPPP study group. Yokoyama K, et al. Among authors: ando k. Res Pract Thromb Haemost. 2018 Apr 15;2(2):274-281. doi: 10.1002/rth2.12097. eCollection 2018 Apr. Res Pract Thromb Haemost. 2018. PMID: 30046729 Free PMC article.
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K, Ohtsu H, Arakawa Y, Kubota K, Yamaguchi T, Nagase M, Yamada A, Fujita T; Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Study Investigators. Ando K, et al. Hypertens Res. 2010 Jun;33(6):616-21. doi: 10.1038/hr.2010.46. Epub 2010 Apr 9. Hypertens Res. 2010. PMID: 20379190 Clinical Trial.
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014).
Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Shimamoto K, et al. Among authors: ando k. Hypertens Res. 2014 Apr;37(4):253-390. doi: 10.1038/hr.2014.20. Hypertens Res. 2014. PMID: 24705419 No abstract available.
3,707 results